IL7RA haplotypes | Adjusted |
---|
rs6897932 | rs987106 | rs3194051 | Freq. | Outcomes | aOR (95% CI) | p value |
---|
C | T | A | 47.9% | F ≥ 3 | 2.01 (1.19;3.40) |
0.007
|
| | | | APRI ≥1.5 | 1.98 (1.06;3.71) |
0.028
|
| | | | FIB4 ≥3.25 | 2.69 (1.10;6.60) |
0.023
|
| | | | A3 | NA | – |
C | A | G | 31.5% | F ≥ 3 | 0.42 (0.22;0.78) |
0.004
|
| | | | APRI ≥1.5 | 0.45 (0.22;0.94) |
0.026
|
| | | | FIB4 ≥3.25 | 0.24 (0.07;0.76) |
0.007
|
| | | | A3 | NA | – |
T | A | A | 20.1% | F ≥ 3 | 0.86 (0.44;1.67) | 0.647 |
| | | | APRI ≥1.5 | 0.92 (0.42;2.04) | 0.838 |
| | | | FIB4 ≥3.25 | 1.07 (0.35;3.26) | 0.904 |
| | | | A3 | NA | – |
- P values were calculated by multivariate logistic regression adjusted by the most important clinical and epidemiological characteristics (see “Statistical analysis” section). Statistically significant differences are shown in italics.
-
95% CI 95% of confidence interval, aOR adjusted odds ratio, p value level of significance, A3 severe activity grade (Metavir), F ≥ 3 advanced liver fibrosis (Metavir), APRI aspartate aminotransferase to platelet ratio index, NA not available due to a low number of patients in one of the groups.